Low preoperative hepcidin concentration as a risk factor for mortality after cardiac surgery: A pilot study Anja Haase-Fielitz, PharmD, Michael Plaß,

Slides:

Advertisements

Similar presentations

John W. Pickering, PhD, Matthew T. James, MD, PhD, FRCPC, Suetonia C

Advertisements

Society of Thoracic Surgeons 2008 cardiac risk models predict in-hospital mortality of heart valve surgery in a Chinese population: A multicenter study

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Manuel J. Antunes, MD, PhD, DSc

Proteinuria predicts postcardiotomy acute kidney injury in patients with preserved glomerular filtration rate Szu-Yuan Li, MD, Chiao-Lin Chuang, MD,

Renal function and outcome after heart transplantation

Prediction of severe acute kidney injury after pediatric cardiac surgery with the use of novel biomarkers: A new trend in clinical research and risk stratification

Acute impact of left ventricular unloading by left ventricular assist device on the right ventricle geometry and function: Effect of nitric oxide inhalation

Acute kidney injury defined according to the ‘Risk,’ ‘Injury,’ ‘Failure,’ ‘Loss,’ and ‘End- stage’ (RIFLE) criteria after repair for a ruptured abdominal.

Update on acute kidney injury after cardiac surgery

The cardiac surgery–associated neutrophil gelatinase-associated lipocalin (CSA-NGAL) score: A potential tool to monitor acute tubular damage Hilde R.H.

Management of Acute Kidney Injury: Core Curriculum 2018

Ludhmila A. Hajjar, MD, PhD, Juliano P. Almeida, MD, Julia T

Prolonged QTc affects short-term and long-term outcomes in patients with normal left ventricular function undergoing cardiac surgery Nattachai Anantasit,

Cardiac surgery–associated neutrophil gelatinase–associated lipocalin score for postoperative acute kidney injury: What is the clinical implication?

The impact of acute kidney injury on midterm outcomes after coronary artery bypass graft surgery: A matched propensity score analysis Sean Gallagher,

Alina M. Robert, MD, Robert S. Kramer, MD, Lawrence J

Intrinsic cardiac stem cells are essential for regeneration

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

Volatile anesthetics in preventing acute kidney injury after cardiac surgery: A systematic review and meta-analysis Jieru Cai, MD, Rende Xu, MD, PhD,

Definition of postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass: One size doesn't fit all David Faraoni, MD,

Memorial for Michael Davidson, MD

Neutrophil gelatinase–associated lipocalin: A promising biomarker for detecting cardiac surgery–associated acute kidney injury Dinna N. Cruz, MD, Claudio.

Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement Ole Lund, MD, PhD, Martin Bland,

The lord of the rings Antonio Miceli, MD, PhD

Esophagectomy versus endoscopic resection for patients with early-stage adenocarcinoma: Mercedes versus Tesla Toni Lerut, MD The Journal of Thoracic.

Reduced pleural drainage, length of stay, and readmissions using a modified Fontan management protocol Nancy A. Pike, PhD, Carol A. Okuhara, MN, Joy.

Franco Stella, MD, PhD, Francesco Petrella, MD

The variability of the mitral valve anatomy and terminology

Does the degree of preoperative mitral regurgitation predict survival or the need for mitral valve repair or replacement in patients with anomalous origin.

All that glitters may not be gold: Changes in serum creatinine may not be the criterion standard for acute kidney injury Rakesh C. Arora, MD, PhD, FRCSC,

Prophylactic nesiritide does not prevent dialysis or all-cause mortality in patients undergoing high-risk cardiac surgery A. Ahsan Ejaz, MD, Tomas D.

Innovation and science: The future of valve design

It's not “just a shunt” but sometimes it should be…

A first start for lung transplantation?

Right ventricular failure after cardiac surgery: Why can't right ventricular assist device support fix the problem? Francis D. Pagani, MD, PhD The Journal.

Dennis G. Moledina, MD, Mark A. Perazella, MD

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Michael Lanuti, MD The Journal of Thoracic and Cardiovascular Surgery

Jeevanantham Rajeswaran, PhD, Eugene H. Blackstone, MD

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

Daniel T. Engelman, MD, FACS, Michael J. Germain, MD

Internal validation of risk models in lung resection surgery: Bootstrap versus training- and-test sampling Alessandro Brunelli, MD, Gaetano Rocco, MD

The Ross procedure: Time to reevaluate the guidelines

Preoperative and intraoperative variables to predict mortality: Which comes first, the chicken or the egg? Umberto Benedetto, MD, PhD, Gianni D. Angelini,

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Are racial differences in hospital mortality after coronary artery bypass graft surgery real? A risk-adjusted meta-analysis Umberto Benedetto, MD, PhD,

Prognosis and “granularity”: Building on staging foundations?

The harder one looks, the more one finds

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

Severe tricuspid or mitral regurgitation in inoperable patients with aortic stenosis. Can we leave them alone? Juan A. Crestanello, MD The Journal of.

The future of cardiac surgery training: A survival guide

Apparently, size matters…in congenital heart disease and brain injury

Prosthesis–patient mismatch after aortic valve replacement predominantly affects patients with preexisting left ventricular dysfunction: Effect on survival,

The continuing challenge of congenital heart disease in China

Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement Todd M. Dewey,

Ralph E. Delius, MD The Journal of Thoracic and Cardiovascular Surgery

After neoadjuvant chemoradiation therapy, predicted pulmonary function may be reduced by 10% Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular.

“The more things change…”: The challenges ahead

Leukoreduction program for red blood cell transfusions in coronary surgery: Association with reduced acute kidney injury and in-hospital mortality Gianpaolo.

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Commentary: Avoiding acute kidney injury after cardiac operations: Searching for the holy grail is not easy Victor A. Ferraris, MD, PhD The Journal.

First in line for robotic surgery: Would you want to know?

Ryan R. Davies, MD The Journal of Thoracic and Cardiovascular Surgery

Preoperative PFTs: The answer is blowing in the wind

Incidence of postoperative acute kidney injury in patients with chronic kidney disease undergoing minimally invasive valve surgery Gerson D. Valdez,

European Society of Thoracic Surgeons preoperative mediastinal staging guidelines: From face validity to external validity Alessandro Brunelli, MD The.

Of mice and men… The Journal of Thoracic and Cardiovascular Surgery

Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: A randomized trial Vito A. Mannacio, MD, Domenico Iorio, MD, Vincenzo.

Presentation transcript:

Low preoperative hepcidin concentration as a risk factor for mortality after cardiac surgery: A pilot study Anja Haase-Fielitz, PharmD, Michael Plaß, MD, Hermann Kuppe, MD, Roland Hetzer, MD, Vaughn Ostland, PhD, Sabine Westphal, MD, Juliane Hoffmann, MD, John Prowle, MD, Peter Rene Mertens, MD, Mark Westerman, PhD, Rinaldo Bellomo, MD, Michael Haase, MD The Journal of Thoracic and Cardiovascular Surgery Volume 145, Issue 5, Pages 1380-1386 (May 2013) DOI: 10.1016/j.jtcvs.2012.09.003 Copyright © 2013 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Preoperative urine hepcidin (A) and plasma hepcidin (B) concentrations in survivors and nonsurvivors. White boxes indicate median hepcidin concentration in nanograms per milliliter with the 25th to 75th percentiles in patients who survived the hospital stay (urine: 325.3 ng/mL; 25th-75th percentile, 120.0-770.1; plasma: 113.1 ng/mL; 25th-75th percentile, 77.7-203.1). Black boxes indicate median hepcidin concentration in nanograms per milliliter with 25th to 75th percentiles in those who died (urine: 15.3 ng/mL; 25th-75th percentile, 0-129.1; plasma: 49.2 ng/mL; 25th-75th percentile, 0-52.2). The Journal of Thoracic and Cardiovascular Surgery 2013 145, 1380-1386DOI: (10.1016/j.jtcvs.2012.09.003) Copyright © 2013 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Area under the curve–receiver operating characteristic analyses (AUC-ROC) of preoperative urine and plasma hepcidin for in-hospital mortality (A), requirement of postoperative renal replacement therapy (RRT) initiation (B) and acute kidney injury (AKI; risk, injury, failure, loss of function, end-stage renal disease [RIFLE]) (C). CI, Confidence interval. The Journal of Thoracic and Cardiovascular Surgery 2013 145, 1380-1386DOI: (10.1016/j.jtcvs.2012.09.003) Copyright © 2013 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Preoperative urine hepcidin (A) and plasma hepcidin (B) concentrations in patients requiring renal replacement therapy (RRT) and in those who did not. White boxes indicate median hepcidin concentration in nanograms per milliliter with 25th to 75th percentiles in patients not requiring RRT. Gray boxes indicate median hepcidin concentration in nanograms per milliliter with 25th to 75th percentiles in patients with RRT initiation. The Journal of Thoracic and Cardiovascular Surgery 2013 145, 1380-1386DOI: (10.1016/j.jtcvs.2012.09.003) Copyright © 2013 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 Preoperative urine and plasma hepcidin concentrations in patients with acute kidney injury (AKI) and without AKI. White boxes indicate median urine hepcidin concentration in nanograms per milliliter with 25th to 75th percentiles (no-AKI: median urine hepcidin concentration, 326.6 ng/mL; 25th-75th percentile, 117.5-692.6; AKI: median urine hepcidin concentration, 133.6 ng/mL; 25th-75th percentile, 15.2-263.6). Gray boxes indicate median plasma hepcidin concentration in nanograms per milliliter with 25th to 75th percentiles (no-AKI: median plasma hepcidin concentration, 112.2 ng/mL; 25th-75th percentile, 77.6-203.4; AKI: median plasma hepcidin concentration, 55.2 ng/mL; 25th-75th percentile, 50.0-145.7). The Journal of Thoracic and Cardiovascular Surgery 2013 145, 1380-1386DOI: (10.1016/j.jtcvs.2012.09.003) Copyright © 2013 The American Association for Thoracic Surgery Terms and Conditions